J. Puttemans

发表

CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma

D. Hose, S. Muyldermans, N. Devoogdt, 2021, Oncoimmunology.

Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon

C. Heirman, K. Thielemans, C. Goyvaerts, 2016, Molecular therapy. Nucleic acids.

The Design and Preclinical Evaluation of a Single-Label Bimodal Nanobody Tracer for Image-Guided Surgery

N. Devoogdt, S. Hernot, F. V. van Leeuwen, 2021, Biomolecules.

Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon.

C. Heirman, K. Thielemans, C. Goyvaerts, 2016, Molecular therapy. Nucleic acids.

Preclinical Targeted α- and β−-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies

A. Windhorst, N. Devoogdt, Q. Lecocq, 2020, Cancers.

Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer

N. Devoogdt, Y. De Vlaeminck, Q. Lecocq, 2021, EJNMMI Research.

Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.

P. Albertsson, V. Caveliers, T. Lahoutte, 2019, Molecular pharmaceutics.

Decorating sdAbs with Chelators: Effect of Conjugation on Biodistribution and Functionality

S. Hernot, T. Lahoutte, G. Raes, 2021, Pharmaceuticals.

Imaging of Glioblastoma Tumor-Associated Myeloid Cells Using Nanobodies Targeting Signal Regulatory Protein Alpha

S. Muyldermans, N. Devoogdt, K. Movahedi, 2021, Frontiers in Immunology.

Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and Metastases

N. Devoogdt, T. Lahoutte, J. Puttemans, 2019, Pharmaceutics.

The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy

N. Devoogdt, T. Lahoutte, F. Bruchertseifer, 2021, Molecular Cancer Therapeutics.

Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment

N. Devoogdt, Q. Lecocq, C. Goyvaerts, 2023, The Journal of Nuclear Medicine.

Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle

Marleen Keyaerts, Nick Devoogdt, Tony Lahoutte, 2016, Expert opinion on biological therapy.

Improved Debulking of Peritoneal Tumor Implants by Near-Infrared Fluorescent Nanobody Image Guidance in an Experimental Mouse Model

N. Devoogdt, S. Hernot, T. Lahoutte, 2018, Molecular Imaging and Biology.

Improved Debulking of Peritoneal Tumor Implants by Near-Infrared Fluorescent Nanobody Image Guidance in an Experimental Mouse Model

N. Devoogdt, S. Hernot, T. Lahoutte, 2018, Molecular Imaging and Biology.

Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties

N. Devoogdt, Y. De Vlaeminck, K. De Veirman, 2024, International journal of molecular sciences.

Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization

N. Devoogdt, Y. De Vlaeminck, Q. Lecocq, 2024, Frontiers in immunology.